Edition:
United Kingdom

miRagen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

7.35USD
4:57pm BST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$7.35
Open
$7.36
Day's High
$7.49
Day's Low
$7.24
Volume
17,059
Avg. Vol
75,121
52-wk High
$15.79
52-wk Low
$5.01

Chart for

About

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product... (more)

Overall

Beta: 1.97
Market Cap(Mil.): $202.81
Shares Outstanding(Mil.): 21.48
Dividend: --
Yield (%): --

Financials

  MGEN.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -11.08 -- --
ROI: -87.08 1.56 14.38
ROE: -90.87 2.43 16.07

BRIEF-Miragen Therapeutics Reports Q1 Loss Per Share $0.18

* MIRAGEN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Miragen Announces Interim Data From Phase 1 Trial Of Cobomarsen In Mycosis Fungoides

* MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES

08 May 2018

BRIEF-Miragen Therapeutics Announces New Data Showing Administration Of MRG-110 Improved Tissue Perfusion And Wound Healing

* MIRAGEN THERAPEUTICS ANNOUNCES NEW DATA SHOWING ADMINISTRATION OF MRG-110 IMPROVED TISSUE PERFUSION AND WOUND HEALING IN LATE STAGE PRECLINICAL STUDIES

27 Apr 2018

BRIEF-Miragen Therapeutics Reports Qtrly ‍loss Per Share $0.29​

* MIRAGEN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

14 Mar 2018

BRIEF-Miragen Therapeutics Prices Public Offering Of Common Stock

* MIRAGEN THERAPEUTICS, INC. PRICES PUBLIC OFFERING OF COMMON STOCK

08 Feb 2018

BRIEF-miRagen Therapeutics Announces Proposed Public Offering Of Common Stock

* MIRAGEN THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

05 Feb 2018

Earnings vs. Estimates